In this prospective multicenter trial, a prior developed unique MRI acquisition and reporting protocol, IMPROD bpMRI (NCT01864135), enabled the detection of 97% (143/146) of men with Gleason score ≥3+4. IMPROD bpMRI consists of T2-weighted imaging and three separate diffusion weighted imaging acquisitions with acquisition time <15 minutes. IMPROD bpMRI appears to be a powerful tool for improved prostate cancer risk stratification in men with a clinical suspicion of prostate cancer based on elevated PSA and/or digital rectal examination. Public access to all data is provided at the following addresses: http://petiv.utu.fi/improd and http://petiv.utu.fi/multiimprod
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords